Literature DB >> 19818243

Adding psychotherapy to pharmacotherapy in the treatment of depressive disorders in adults: a meta-analysis.

Pim Cuijpers1, Jack Dekker, Steven D Hollon, Gerhard Andersson.   

Abstract

OBJECTIVE: A considerable number of studies has examined whether adding psychotherapy to pharmacotherapy results in stronger effects than pharmacotherapy alone. However, earlier meta-analyses in this field have included only a limited number of available studies and did not conduct extended subgroup analyses to examine possible sources of heterogeneity. DATA SOURCES: We used a database derived from a comprehensive literature search in PubMed, PsycINFO, EMBASE, and the Cochrane Central Register of Controlled Trials for studies published from 1966 to January 2008 that examined the psychological treatment of depression. The abstracts of these studies were identified by combining terms indicative of psychological treatment and depression. STUDY SELECTION: We included randomized trials in which the effects of a pharmacologic treatment were compared to the effects of a combined pharmacologic and psychological treatment in adults with a depressive disorder. DATA EXTRACTION: For each of the studies, we calculated a standardized mean effect size indicating the difference between pharmacotherapy and the combined treatment at posttest. We also coded major characteristics of the population, the interventions, and the quality and design of the study. DATA SYNTHESIS: Twenty-five randomized trials, with a total of 2,036 patients, were included. A mean effect size of d = 0.31 (95% CI, 0.20 approximately 0.43) was found for the 25 included studies, indicating a small effect in favor of the combined treatment over pharmacotherapy alone. Studies aimed at patients with dysthymia resulted in significantly lower effect sizes compared to studies aimed at patients with major depression, a finding that suggests that the added value of psychotherapy is less in patients with dysthymia. The dropout rate was significantly lower in the combined treatment group compared to the pharmacotherapy only group (OR = 0.65; 95% CI, 0.50 approximately 0.83).
CONCLUSIONS: Psychotherapy seems to have an additional value compared to pharmacotherapy alone for depression. Copyright 2009 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19818243     DOI: 10.4088/JCP.09r05021

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  66 in total

1.  Combined pharmacotherapy and psychotherapy for social anxiety disorder.

Authors:  Dan J Stein; Jonathan C Ipser
Journal:  Curr Psychiatry Rep       Date:  2010-08       Impact factor: 5.285

2.  Mood matters: a national survey on attitudes to depression.

Authors:  John R Kelly; Mary Cosgrove; Cian Judd; Kathy Scott; Aoibheann Mc Loughlin; Veronica O'Keane
Journal:  Ir J Med Sci       Date:  2019-04-02       Impact factor: 1.568

3.  Treatment for Depression and Health-Related Quality of Life among Adults with Arthritis.

Authors:  Drishti Shah; Pragya Rai; Nilanjana Dwibedi; Usha Sambamoorthi
Journal:  Psychiatr Q       Date:  2018-03

4.  Advances in the Management of Treatment-Resistant Depression.

Authors:  Paul E Holtzheimer
Journal:  Focus (Am Psychiatr Publ)       Date:  2010

5.  Depression in the Primary Care Setting. Reply.

Authors:  Lawrence T Park; Carlos A Zarate
Journal:  N Engl J Med       Date:  2019-06-06       Impact factor: 91.245

6.  Management of Mental Health Disorders, Substance Use Disorders, and Suicide in Adults with Spinal Cord Injury: Clinical Practice Guideline for Healthcare Providers.

Authors:  Charles H Bombardier; Casey B Azuero; Jesse R Fann; Donald D Kautz; J Scott Richards; Sunil Sabharwal
Journal:  Top Spinal Cord Inj Rehabil       Date:  2021

7.  Usual Primary Care Provider Characteristics of a Patient-Centered Medical Home and Mental Health Service Use.

Authors:  Audrey L Jones; Susan D Cochran; Arleen Leibowitz; Kenneth B Wells; Gerald Kominski; Vickie M Mays
Journal:  J Gen Intern Med       Date:  2015-06-03       Impact factor: 5.128

8.  National trends in second-generation antipsychotic augmentation for nonpsychotic depression.

Authors:  Tobias Gerhard; Ayse Akincigil; Christoph U Correll; Neil J Foglio; Stephen Crystal; Mark Olfson
Journal:  J Clin Psychiatry       Date:  2014-05       Impact factor: 4.384

Review 9.  Economic evidence for the clinical management of major depressive disorder: a systematic review and quality appraisal of economic evaluations alongside randomised controlled trials.

Authors:  E Karyotaki; D Tordrup; C Buntrock; R Bertollini; P Cuijpers
Journal:  Epidemiol Psychiatr Sci       Date:  2016-06-22       Impact factor: 6.892

Review 10.  Depression in type 2 diabetes mellitus: prevalence, impact, and treatment.

Authors:  Katherine Semenkovich; Miriam E Brown; Dragan M Svrakic; Patrick J Lustman
Journal:  Drugs       Date:  2015-04       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.